Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine
Summary
The STEP 1 trial was a 68-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly subcutaneous semaglutide 2.4 mg for weight management in 1,961 adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) without diabetes. Participants receiving semaglutide achieved a mean body weight reduction of 14.9% compared to 2.4% with placebo.
Key Findings
- Mean change in body weight was -14.9% with semaglutide vs -2.4% with placebo at 68 weeks
- 86.4% of semaglutide participants achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss
- Semaglutide led to significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, C-reactive protein, and lipid levels
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Available Research Products
Related Studies
View all →Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, et al.
New England Journal of Medicine
The SUSTAIN-6 trial was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial evaluating subcutaneous semaglutide (0.5 mg or 1.0 mg weekly) in 3,297 patients with type 2 diabetes at high cardiovascular risk over a median of 2.1 years. Semaglutide significantly reduced the primary composite endpoint of major adverse cardiovascular events (MACE) by 26%.
- Semaglutide reduced the primary MACE composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 26% compared to placebo (HR 0.74, 95% CI 0.58-0.95)
- Non-fatal stroke was reduced by 39% and non-fatal myocardial infarction by 26% in the semaglutide group